Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Total Valuation
Corcept Therapeutics has a market cap or net worth of $7.66B. The enterprise value is $1.73B.
Market Cap$7.66B
Enterprise Value$1.73B
Share Statistics
Corcept Therapeutics has 106,044,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding106,044,690
Owned by Insiders11.53%
Owned by Institutions17.46%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 17.09%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)17.09%
Return on Capital Employed (ROCE)0.20
Revenue Per Employee1.35M
Profits Per Employee282.42K
Employee Count500
Asset Turnover0.80
Inventory Turnover0.88
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 37.23. Corcept Therapeutics’s PEG ratio is -10.37.
PE Ratio37.23
PS Ratio0.00
PB Ratio4.32
Price to Fair Value7.65
Price to FCF18.09
Price to Operating Cash Flow18.03
PEG Ratio-10.37
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 675.04M and earned 139.73M in profits. Earnings per share was 1.35.
Revenue675.04M
Gross Profit664.16M
Operating Income136.95M
Pretax Income161.49M
Net Income139.73M
EBITDA136.95M
Earnings Per Share (EPS)1.35
Cash Flow
In the last 12 months, operating cash flow was 179.44M and capital expenditures -2.28M, giving a free cash flow of 177.16M billion.
Operating Cash Flow179.44M
Free Cash Flow177.16M
Free Cash Flow per Share1.67
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change126.09%
50-Day Moving Average72.45
200-Day Moving Average58.10
Relative Strength Index (RSI)47.34
Average Volume (3m)1.33M
Important Dates
Corcept Therapeutics upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.
Last Earnings DateMay 5, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
Corcept Therapeutics as a current ratio of 3.35, with Debt / Equity ratio of 0.23%
Current Ratio3.35
Quick Ratio3.26
Debt to Market Cap<0.01
Net Debt to EBITDA-0.88
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid 20.28M in taxes.
Income Tax20.28M
Effective Tax Rate0.13
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 37.10, with an EV/FCF ratio of 25.94.
EV to Sales7.53
EV to EBITDA37.10
EV to Free Cash Flow25.94
EV to Operating Cash Flow25.65
Balance Sheet
Corcept Therapeutics has $322.76M in cash and marketable securities with $6.83M in debt, giving a net cash position of -$315.93M billion.
Cash & Marketable Securities$322.76M
Total Debt$6.83M
Net Cash-$315.93M
Net Cash Per Share-$2.98
Tangible Book Value Per Share$6.58
Margins
Gross margin is 98.66%, with operating margin of 20.29%, and net profit margin of 20.70%.
Gross Margin98.66%
Operating Margin20.29%
Pretax Margin23.92%
Net Profit Margin20.70%
EBITDA Margin20.29%
EBIT Margin20.29%
Analyst Forecast
The average price target for Corcept Therapeutics is $139.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$139.33
Price Target Upside95.58% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast30.93%
EPS Growth Forecast11.78%